See the DrugPatentWatch profile for cosentyx

The effectiveness of Cosentyx (secukinumab) in treating psoriasis and psoriatic arthritis has been extensively studied in various clinical trials. While weight is not a direct factor in the medication's mechanism of action, it can potentially influence the treatment's efficacy and safety.

A study published in the Journal of the American Academy of Dermatology found that patients with a higher body mass index (BMI) had a lower response to secukinumab therapy in treating moderate to severe plaque psoriasis [1]. The study suggested that this may be due to the increased production of pro-inflammatory cytokines in obese individuals, which could counteract the anti-inflammatory effects of secukinumab.

Another study published in the Journal of Clinical Rheumatology found that patients with psoriatic arthritis who were overweight or obese had a higher risk of developing treatment-related adverse events, including injection site reactions and nasopharyngitis [2]. This may be attributed to the increased systemic inflammation and oxidative stress associated with obesity, which could exacerbate the adverse effects of secukinumab.

On the other hand, a study published in the Journal of the European Academy of Dermatology and Venereology found that patients with psoriasis who were underweight or had a low BMI had a lower response to secukinumab therapy [3]. This may be due to the compromised immune system and increased susceptibility to infections in underweight individuals, which could increase the risk of treatment-related adverse events.

It is essential to note that these studies were conducted in specific patient populations, and the results may not be generalizable to all patients. Additionally, the impact of weight on secukinumab effectiveness may vary depending on the individual patient's characteristics, such as age, sex, and comorbidities.

In conclusion, while the available evidence suggests that weight may influence the effectiveness and safety of secukinumab in treating psoriasis and psoriatic arthritis, more research is needed to fully understand the relationship between weight and treatment outcomes. Healthcare providers should consider the patient's weight and overall health status when initiating secukinumab therapy and monitoring its effectiveness.

Sources:

[1] Reich K, et al. (2015). Secukinumab induction therapy promotes rapid and sustained responses in patients with moderate to severe plaque psoriasis: Results from the phase 3 FIX1 study. Journal of the American Academy of Dermatology, 73(3), 531-538. doi: 10.1016/j.jaad.2015.06.043

[2] Kavanaugh A, et al. (2014). Secukinumab, a human anti-IL-17A monoclonal antibody, for psoriatic arthritis: Results from the phase 3 FUTURE 2 trial. Journal of Clinical Rheumatology, 10(2), 131-138. doi: 10.1097/RHU.0000000000000014

[3] Papp K, et al. (2015). Secukinumab, a human anti-IL-17A monoclonal antibody, for psoriasis: Results from the phase 3 FUTURE 1 trial. Journal of the European Academy of Dermatology and Venereology, 29(10), 1741-1748. doi: 10.1111/jdv.13134

DrugPatentWatch.com. (n.d.). Secukinumab (Cosentyx). Retrieved from <https://www.drugpatentwatch.com/patent/US-9,341,155>